Rolf Muller, Ph.D.
Chief Executive Officer
Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets. Prior to joining BioFluidica he was the Founder and President of Biomatrica, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.
Steven A. Soper, Ph.D.
Cofounder and Chief Technology Officer
Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experiences in the CTC research area along with being the author of five patents currently licensed by BioFluidica. He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently the Foundation Distinguished Professor in Chemistry and Mechanical Engineering at Kansas University. He is also Director of the Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.
Judy Muller-Cohn, Ph.D
Chief Operating Officer
Judy Muller-Cohn, Ph.D. is a biotechnology leader moving scientific ideas to commercial products. She manages operations at BioFluidica overseeing commercial development of the company’s ground breaking technology to serve the growing need of the cancer diagnostic market. Previously, she founded, and for ten years was CEO, of a successful biotechnology company from idea to financing, product development, patenting, grant management, human resources, and business development. She also serves on the boards of for-profit and non-profit organizations. Judy earned a Ph.D. in microbial biochemistry from Universite Paris VI and conducted her research at the Pasteur Institute in Paris, France.
Angie Purvis, PhD
Angie has a successful track-record bringing diagnostic products to market by successfully combining broad scientific and product development skills and regulatory expertise to create high-quality in vitro diagnostics and laboratory-based diagnostics. Angie successfully implements regulatory strategies and has led the regulatory filing efforts for a variety of in vitro diagnostics in the USA and in other markets around the world. She builds Quality Management Systems for biotech companies, and works with teams to tailor systems to fit the business size and need. Angie has built numerous high-complexity CAP/CLIA laboratories that include a wide range of specialties. She has led the plan of correction and remediation effort for numerous laboratories and has restored processes and validation to meet regulatory expectations. She has strong track record designing and validating diagnostics for infectious disease and oncology. Angie is a board-certified CLIA Laboratory Director for high-complexity testing across the USA.
Angie completed her PhD (Biochemistry) and post-doctoral training at Washington University at the Howard Hughes Medical Institute (HHMI).
Burt De Mill
Most recently, at Lifecode, Inc., a Sequoia Capital and Mayo Ventures backed company, Burt served as Chief Commercial Officer, and was responsible for bringing next-generation sequencing based tumor profiling services to the community oncologist. His role included business strategy development, sales & marketing channels, pricing, and third-party reimbursement strategy. Mr. De Mill also served as a Board Director at LABS, Inc., Centennial Colorado from 2015 to 2018.
Previously he served as the Chief Commercial Officer at Lineagen, Inc., where he successfully directed the launch of FirstStepDx, a novel genetic test for autism and developmental delay in children. As the Sr. Vice President, Sales & Marketing at Genoptix Medical Labs from 2005 to 2010, he scaled revenues from $4M to $184M in 5 years, earning Genoptix a top spot on the Deloitte LLP "Fast 50" companies in North America, as well as a successful NASDAQ IPO in October 2007. He has also held senior management positions at Invitrogen (Thermo Fisher) and Amersham Biosciences (GE Health). Burt received a B.S. degree in Microbiology from the University of Maryland, College Park.
Doug Paulin, CPA
Doug Paulin of Signature Analytics San Diego, LLC was appointed our Chief Financial Officer effective March 12th, 2021. He joined the accounting services firm of Signature Analytics in June of 2020. He held positions at Aernos, from June 2019 to March 2020. From March 2016 to 2018, he worked at Sonos, Inc. and served as the EMEA Director of Finance, helping them complete their IPO in 2018 successfully raising over $200M. He has also served in positions at Autonet Mobile, Lear, Inc., PayLease, Inc. and the Investment Banking Firm Cove Partners. Doug received a Bachelor of Science in Finance and a minor in Information Technology from Babson College. He is actively licensed Certified Public Accountant.
Mateusz Hupert, Ph.D.
Director of Instrumentation & Diagnostic Development
Dr. Hupert has 10 years of experience in the area of microfabrication, in particular the area of fabrication structures in plastics using replication-based technologies, such as hot embossing and injection molding. He is currently the Director of Microfabrication Technology at BioFluidica and is the PI on the SBIR grants that BioFluidica currently holds. In addition, he has been instrumental in the design and the building of the instrumentation that has evolved as a result of our SBIR grants including instruments for fluorescence imaging of selected CTCs for immunophenotyping. Dr. Hupert also has experiences in fluidic mechanics and electrochemistry as part of his graduate studies.